See a letter to the Angelman community. Ultragenyx reported positive interim data from the ongoing Phase 1/2 study in patients living with deletion genotype Angelman syndrome after treatment with investigational GTX-102. From company press release: “The totality of these […]
Read moreRoche has made the difficult decision not to move forward with a new clinical trial for rugonersen and has initiated the search for an external partner to take over the development. The conclusion of this trial undoubtedly brings feelings of […]
Read moreAURORA, IL – Angelman Syndrome Foundation (ASF) proudly announces the launch of the Jacob Pritzker Fellowship Program in honor of late board president Fred Pritzker. The Jacob Pritzker Fellowship Program was created to address the ever-increasing need for more physicians who […]
Read more
The Angelman Syndrome Foundation is proud to announce their partnership with Genefund Future Angelman Syndrome (GFAS Ukraine) to launch a new clinic to better serve the community in Ukraine. “Bright people are always visible in dark times. In the most […]
Read more
The Angelman Syndrome Foundation is proud to announce their partnership with AngelmanUK to launch new clinics and expand existing clinics to better serve the community in the UK. “AngelmanUK is delighted to collaborate with the Angelman Syndrome Foundation (ASF) on […]
Read more
Angelman Syndrome Foundation (ASF) proudly announces the collaboration with OVID Therapeutics to advance understanding of AS via a contribution of crucial data collected in Ovid’s clinical trial for Angelman syndrome to the LADDER database. “The most important gift that industry […]
Read more
Angelman Syndrome Foundation (ASF) and Dup15q Alliance proudly announce their strategic partnership to launch the LADDER Learning Network, a new medical network specifically designed for individuals with Angelman syndrome (AS) and dup15q—two rare disorders affecting the q-arm of the […]
Read more
As part of a 2020 ASF funded study, Ben Philpot, PhD and Matt Judson, PhD at UNC School of Medicine have been developing a gene therapy strategy as a method to restore function of UBE3A. The early results were published […]
Read more